Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: A preliminary study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 12, 2003, Pages 578-586

  Konishi, H ^a   Nishio, S ^a   Tsutamoto, T ^b   Minouchi, T ^a   Yamaji, A ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Brain natriuretic peptide; Heart failure; Serum carvedilol concentration

Indexed keywords

AMIODARONE; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROPRANOLOL; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLIC CLEARANCE RATE; PATIENT MONITORING; PROTEIN BLOOD LEVEL; STEADY STATE; TREATMENT OUTCOME;

EID: 0348111300     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41578     Document Type: Article

References (31)

1. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G Cohn JN 2003 Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107: 1278-1283
2. Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P 2001 Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 15: 95-109
3. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N 1996 Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94: 2807-2816
4. CIBIS-II Investigators and Committees 1999 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353: 9-13
5. Cohn JN 1988 Current therapy of the failing heart. Circulation 78: 1099-1107
6. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA 1996 Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94: 2800-2806
7. Foody JM, Farrell MH, Krumholz HM 2002 β-Blocker therapy in heart failure. Scientific review. JAMA 287: 883-889
8. Fujimaki M, Hakusui H, Hasegawa Y, Ajima H, Ota H, Igarashi S, Yamamura H 1990 Pharmacokinetics of carvedilol (DQ-2466) in healthy subjects. Jpn J Clin Pharmacol Ther 21: 415-424
9. Handa S, Hosoda S, Sasayama S, Hori M, Kitabatake A, Toyo-oka T, Yokoyama M, Matsuzaki M, Takeshita A, Matsui K, Origasa H 2000 Multicenter carvedilol heart failure assessment (MUCHA) trial. J Card Fail 6 (Suppl 3): 81
10. + channels in cultured bovine adrenal medullary cells. J Pharmacol Exp Ther 302: 212-218
11. Kato R, Ueno K, Tsuchishita Y, Yoshimura H, Takada M, Komamura K, Kamakura S, Miyatake K, Shibakawa M (2002) A simple assay for serum carvedilol concentration by HPLC and its clinical application. Jpn J Pharm Health Care Sci 28: 9-15
12. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M 2001 Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141: 925-932
13. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, Delong G, Packer M 1995 Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92: 1499-1506
14. Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL 1987 A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 10 (Suppl 11): S89-S93
15. MERIT-HF Study Group 1999 Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007
16. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L 2000 Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102: 546-551
17. Mukoyama M, Nakao K, Hosoda K, Saga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H 1991 Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412
18. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T 2000 Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49: 244-253
19. Oldham HG, Clarke SE 1997 In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 25: 970-977
20. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowits FD, Bristow MR 1995 Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind, randomized study. J Am Coll Cardiol 25: 1225-1231
21. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K 1996 Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93: 1963-1969
22. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, Lejemtel TH, Young ST, Lukas MA, Shusterman NH 1996a Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 94: 2793-2799
23. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH 1996b The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349-1355
24. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL 2001 Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658
25. Tateishi T 2002 CYP polymorphism in Japanese and drugs for cardiovascular system. Jpn J Ther Drug Monit 19: 89-90
26. Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, Jorkasky D 2000 Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 40: 844-853
27. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M 1997 Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509-516
28. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Kinoshita M 2001 Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J Card Fail 7: 322-328
29. von Möllendorff E, Reiff K, Neugebauer G (1987) Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 33: 511-513
30. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe WA, Tremmel KD, Brisotw MR 1996 Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 17: 8-16
31. Zhou HH, Wood AJJ 1995 Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57: 518-524